Vertex ( ($VERX) ) has shared an update. On October 30, 2025, Vertex‘s Board of Directors authorized a stock repurchase program for up to $150 ...

Vertex, Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), a leading global provider of indirect tax solutions, today announced financial results for its third quarter ended September 30, 2025 and the ...

Vertex, Inc. shares have plunged over 60% YTD, but valuation is now compelling after a post-earnings dip. Learn more about VERX stock here.

The potential approval of Vertex’s IgAN therapy povetacicept in 2026 comes amid launch headwinds for the company’s non-opioid ...

The stock, which is down more than 61% in 2025, sold off after reporting a Q3 EPS beat missing on revenue expectations.

Vertex Pharmaceuticals VRTX reported adjusted earnings of $4.80 per share for the third quarter of 2025, surpassing the Zacks ...

Vertex Minerals Ltd. ( ($AU:VTX) ) has issued an announcement. Vertex Minerals Limited has commenced underground ore production at the Reward Gold ...

If you're an individual retail investor searching for healthcare stocks you can buy and hold for at least 20 years, here are ...

CRISPR Therapeutics is likely to witness an earnings beat as Casgevy sales climb and new CAR-T and in-vivo programs advance.

The post Market Analysis: Nov 4th, 2025 appeared first on Stock Target Advisor.

These awards reflect the vision of organization founder Dr. Irving Fradkin, whose pioneering work in establishing ...